PRRX1 and pulmonary fibrosis: Endotracheal administration of this ASO from day 7 in the bleomycin-induced lung fibrosis model allowed us to inhibit locally and efficiently Prrx1 TFs during the active fibrosis phase in a ‘curative’ protocol.